Clinical Trial Details

Short Title
Official Title
Treatment for Very Low Favorable Histology Wilms Tumor

Participants in this research study have a favorable histology Wilms tumor that has some risk of returning after treatment. The purpose of this research study is to find out if subjects with a higher risk of having their tumor return will benefit from the addition of doxorubicin or the current standard treatment. Approximately 5 people will take part in this study at the University of Iowa. Study involvement will last for 25 weeks and will have follow-up examinations and tests for about 5 years.

Start Date
February 18, 2009
End Date
August 17, 2013
Gender Preference
Age Group
0 - 99 years
Principal Investigator
Ayman El-Sheikh, MD
Contact Info

Julie de la Garza, 319-356-3749

AREN0532 ; cancer ; doxorubicin ; el-sheikh ; IRB#200812777 ; pediatric ; phase 3 ; phase III ; Wilms tumor ;

We'd welcome your feedback!

Please help us improve your experience on our website by completing a brief survey

Yes, I'll give feedback No, Thanks